GlobeNewswire by notified

NEXEN TIRE gets original equipment approval for the eighth-generation BMW 5 Series

Share

- South Korean tire maker gets OE approval for N’FERA SPORT premium tires

SEOUL, South Korea, Oct. 25, 2023 (GLOBE NEWSWIRE) -- NEXEN TIRE, a leading global tire manufacturer, announced that it is supplying original equipment (OE) for the eighth-generation of the BMW 5 Series Sedan.

NEXEN TIRE's N’FERA SPORT supplied as tires for the vehicle, is a European premium sports tire that provides excellent dry and wet performance through a wide longitudinal groove and features asymmetrical patterns. Furthermore, pattern design optimization improves high-speed reliability, handling performance, and noise suppression significantly and the grip was enhanced by the use of new compounds.

In summer tire tests conducted by leading European automobile magazines such as Germany's AutoBild, ADAC, and Ace Lenkrad, the N'FERA SPORT received "strong" and "purchase" recommendation ratings. The tire was also awarded the main prize in the product design category of the 'Red Dot Design Awards' in Germany.

Based on quality and technology through continuous research and development, NEXEN TIRE plans to expand the supply of tires for new cars to global premium car manufacturers and strengthen its competitiveness in the European market.

NEXEN TIRE is supplying its N'FERA SPORT tires in size 225/55 R18 102Y XL.

About NEXEN TIRE

NEXEN TIRE, founded in 1942, is a global tire manufacturer based in South Korea. NEXEN TIRE, one of the world's fastest growing tire manufacturers, currently works with 150 countries and owns four manufacturing plants, two in Korea (Yangsan and Changnyeong) and one in Qingdao, China. In 2019, another plant in Žatec, Czech Republic, went into operation. NEXEN TIRE manufactures tires with advanced technology and design excellence for passenger cars, SUVs, and light trucks. NEXEN TIRE supplies original equipment tires to global automakers in a variety of countries around the world. For the first time among the various tire manufacturers in the world, the company achieved a grand slam of the world's top four design awards in 2014.

For more information, please visit http://www.nexentire.com/international/

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2b4cbcf8-57e8-4bdb-acaf-2ffcc58bc38d

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Lerøy Seafood Group ASA: Record revenue in 2023. Progress towards targets for 2025.28.2.2024 06:30:00 CET | Press release

RECORD REVENUE IN 2023. MAKING PROGRESS TOWARDS 2025 TARGETS 2023 marks the first year in Lerøy's history where revenue exceeds NOK 30 billion. Seafood's position among consumers remains strong. We continue to vigorously work towards developing the most efficient and sustainable value chain for seafood. I am proud of the work our employees do, while acknowledging that the past year has been challenging," says CEO Henning Beltestad. FOURTH QUARTER 2023 DEVELOPMENT In the fourth quarter of 2023, Lerøy delivered an operating profit before biomass adjustments of NOK 765 million. In Farming, we experienced challenges related to string jellyfish and lost feeding days in Lerøy Aurora and accelerated harvest in Lerøy Sjøtroll. In Wild Catch, earnings were approximately the same as the same period the year before. In the VAP S&D segment, there is positive development as previously communicated, as product prices has increased, reflecting the increased raw material costs, and we have gradually s

Lerøy Seafood Group ASA: Rekordomsetning i 2023. Fremgang mot mål for 2025.28.2.2024 06:30:00 CET | Pressemelding

REKORDOMSETNING I 2023 2023 er det første året i Lerøy sin historie at omsetningen overstiger NOK 30 mrd. Sjømatens posisjon hos konsumentene står sterkt. Vi fortsetter med full kraft arbeidet med å utvikle den mest effektive og bærekraftige verdikjeden for sjømat. Jeg er stolt av den jobben vi og våre ansatte gjør, samtidig som vi erkjenner at året som har gått har vært utfordrende, sier konsernleder Henning Beltestad. UTVIKLING I FJERDE KVARTAL 2023 I fjerde kvartal 2023 leverte Lerøy et driftsresultat før biomassejusteringer på NOK 765m. I Havbruk opplevde vi utfordringer knyttet til perlesnor-maneter og tap av fôringsdager i Lerøy Aurora og fremskyndet slakting i Lerøy Sjøtroll. Innen Villfangst ble inntjeningen om lag som samme periode året før. I nedstrømsvirksomhetene i segmentet VAP S&D er det som tidligere kommunisert positiv utvikling ettersom produktprisen nå i større grad reflekterer de økte råvarekostnadene, og vi gradvis har lykkes med operasjonelle forbedringer. Styret i

BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)27.2.2024 21:52:04 CET | Press release

Large phase 2 global study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, is pleased to announce site recruitment for BTI-203, a Phase 2 study of recombinant human gelsolin (rhu-pGSN) for the treatment of Acute Respiratory Distress Syndrome (ARDS) (NCT05947955). The study, A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Recombinant Human Plasma Gelsolin With Standard of Care for Moderate-to-Severe ARDS Due to Pneumonia or Other Infections is being conducted under a contract with BARDA’s Division of Research, Innovation, and Ventures (DRIVe), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. Approximately 80 sites

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons27.2.2024 21:42:24 CET | Press release

Company Announcement COPENHAGEN, Denmark; February 27, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. Please find below a statement of such trading in shares issued by Genmab A/S 1.Details of the person discharging managerial responsibilities / person closely associateda)NameAnthony Pagano2.Reason for the notificationa)Position/statusExecutive Vice President & Chief Financial Officerb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction pla

Capital Increase in Genmab as a Result of Employee Warrant Exercise27.2.2024 21:40:01 CET | Press release

Company Announcement COPENHAGEN, Denmark; February 27, 2024 –Genmab A/S (Nasdaq: GMAB) will increase its share capital by 48,429 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 7,325 shares at DKK 1,025.00, 19,631 shares at DKK 1,032.00, 2,473 shares at DKK 1,050.00, 1,422 shares at DKK 1,161.00, 40 shares at DKK 1,334.50, 1,036 shares at DKK 1,362.50, 6,660 shares at DKK 1,402.00, 129 shares at DKK 1,408.00, and 9,713 shares at DKK 1,615.00. Proceeds to the company are approximately DKK 58.7 million. The increase corresponds to approximately 0.07% of the company's share capital. The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as

HiddenA line styled icon from Orion Icon Library.Eye